BIOMAT Database Logo BIOMAT Database Logo

Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus. 1988

S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Department of Microbiology, University of Madras, India.

In a preliminary study, carriers of hepatitis B virus were treated with a preparation of the plant Phyllanthus amarus for 30 days. 22 of 37 (59%) treated patients had lost hepatitis B surface antigen when tested 15-20 days after the end of the treatment compared with only 1 of 23 (4%) placebo-treated controls. Some subjects have been followed for up to 9 months. In no case has the surface antigen returned. Clinical observation revealed few or no toxic effects. The encouraging results of this preliminary study recommend continued evaluation of this plant and the active principles isolated from it.

UI MeSH Term Description Entries
D008297 Male Males
D010946 Plants, Medicinal Plants whose roots, leaves, seeds, bark, or other constituent parts possess therapeutic, tonic, purgative, curative or other pharmacologic attributes, when administered to man or animals. Herbs, Medicinal,Medicinal Herbs,Healing Plants,Medicinal Plants,Pharmaceutical Plants,Healing Plant,Herb, Medicinal,Medicinal Herb,Medicinal Plant,Pharmaceutical Plant,Plant, Healing,Plant, Medicinal,Plant, Pharmaceutical,Plants, Healing,Plants, Pharmaceutical
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus.
October 1988, Lancet (London, England),
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers.
September 1991, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
In vitro effect of Phyllanthus amarus on hepatitis B virus.
March 1991, The Indian journal of medical research,
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Hepatitis B virus and hepatocellular carcinoma--treatment of HBV carriers with Phyllanthus amarus.
January 1989, Cancer detection and prevention,
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Effect of Phyllanthus amarus on duck hepatitis B virus replication in vivo.
December 1990, Journal of medical virology,
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Hepatitis B virus and primary hepatocellular carcinoma: treatment of HBV carriers with Phyllanthus amarus.
March 1990, Vaccine,
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Phyllanthus amarus and hepatitis B.
October 1990, Lancet (London, England),
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Failure of New Zealand hepatitis B carriers to respond to Phyllanthus amarus.
June 1994, The New Zealand medical journal,
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers.
June 1990, Lancet (London, England),
S P Thyagarajan, and S Subramanian, and T Thirunalasundari, and P S Venkateswaran, and B S Blumberg
Beneficial effects of Phyllanthus amarus for chronic hepatitis B, not confirmed.
May 1991, Journal of hepatology,
Copied contents to your clipboard!